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Noncommunicable diseases (NCDs), including cancer, are responsible for
almost 70% of all deaths worldwide. Tobacco use is a risk factor common
to most NCDs. This article discusses tobacco control policies and high-
lights major achievements and open challenges to reduce smoking preva-
lence and attributable morbidity and mortality in the 21st century. The
introduction of the WHO Framework Convention on Tobacco Control in
2005 has been a key achievement in the field and has already facilitated a
drop in both smoking prevalence and exposure to secondhand smoke.
Indicatively, the size of the worldwide population benefiting from at least
one cost-effective tobacco control policy has quadrupled since 2007. In
addition, plain cigarette packaging has been successfully introduced as a
tobacco control policy, surmounting efforts of the tobacco industry to
challenge this based on trade and investment law. Nevertheless, tobacco
control still faces major challenges. Smoking prevalence needs to be further
reduced in a rather expedited manner. Smoke-free environments should be
extended, and the use of plain tobacco packaging with large pictorial
health warnings for all tobacco products should be further promoted in
some parts of the world. Some of these measures will require prompt deter-
mination and diligence. For example, bold political decisions are needed to
significantly increase real prices of tobacco products through excise taxes,
ban added ingredients that are currently used to increase the attractiveness
of tobacco products and ban the tobacco industry’s corporate social
responsibility initiatives. Finally, the debate on harm reduction strategies
for tobacco control still needs to be resolved.
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1. Introduction
The 1964 US Surgeon General’s Report [1] and numer-
ous other reports have established the terrible conse-
quences of smoking on the health of smokers and
nonsmokers. At the end of the 20th century, tobacco
had caused 100 million deaths worldwide, becoming a
leading cause of totally preventable premature deaths. It
has been predicted that without any additional tobacco
control efforts, one billion people could die from causes
related to tobacco by the end of the 21st century, such
as cancer, heart disease, stroke, lung diseases, diabetes,
and chronic obstructive pulmonary disease [2].
An extremely profitable industry fueled the tobacco
epidemic by selling a highly addictive product taking
advantage of globalization in the second half of the
20th century. Governments and public health organi-
zations became aware of the globalization and the sev-
ere consequences of the tobacco epidemic and its
evolution into a large-scale pandemic [3]. The signifi-
cant economic toll of tobacco, which today amounts
to US$1436 billion, or 1.8% of the world’s annual
gross domestic product [4], was soon realized. At the
same time, governments and public health organiza-
tions recognized that the pandemic needed a global
and coordinated high-level response.
In 1999, WHO initiated the proceedings to create
the Framework Convention for Tobacco Control
(FCTC), the first international treaty under WHO aus-
pices. Followingly, the global community recognized
tobacco use as a severe threat to global health, as well
as a social and economic problem, and began to take
joint international action. This work highlights
achievements in tobacco control in the 21st century
and discusses open challenges (Fig. 1).
2. Achievements of tobacco control
efforts during the first 20 years of the
21st century
2.1. Galvanizing global political will around
international law
The WHO FCTC entered into force in 2005 as bind-
ing law for all treaty parties. As of January 2021, the
treaty was adopted by 181 WHO member states and
the European Union, thereby covering more than
90% of the world’s population. The Protocol to
Eliminate Illicit Trade in Tobacco Products, also
known as Illicit Trade Protocol (ITP), was introduced
under the WHO FCTC in 2018. As of January 2021,
62 WHO FCTC parties had also become parties to
the protocol.
Galvanizing the global political will for implement-
ing the WHO FCTC and the ITP has been a key suc-
cess in tobacco control. These treaties redefine the role
of international law in preventing disease and promot-
ing health. Both treaties seek to establish cooperation
among countries to tackle, for example, cross-border
advertising and illicit trade. Importantly, they seek to
establish international cooperation on matters that
would otherwise be subject to national regulation
because the sovereignty of nations to protect public
health is often challenged by the interests of the pow-
erful transnational tobacco industry. The tobacco com-
panies often seek to expand the tobacco market
through various tactics, including intensive targeting of
women, children, and the poorer parts of society [5].
Therefore, the WHO FCTC and the ITP have solidi-
fied global governance of health matters and the foun-
dation for countries to enact comprehensive, effective
Fig. 1. Tremendous, although insufficient,
progress has been made on tobacco
control during the past 20 years.
Nevertheless, there are still open
challenges, and several measures remain
to be implemented soon: increasing
tobacco taxes, banning the use of
additives, implementing plain packaging,
banning tobacco industry’s corporate
social responsibility activities, and
counteracting the undermining tactics of
the tobacco industry.
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national tobacco control measures that span across all
government sectors.
2.2. Quadrupling the number of people
benefiting from at least one cost-effective
tobacco control policy since 2007
In 2008, WHO introduced the MPOWER package to
assist in implementing the six best-practice cost-effec-
tive interventions defined in the WHO FCTC. The six
MPOWER measures are as follows: (a) Monitor
tobacco use and prevention policies (M); (b) Protect
people from tobacco smoke (P); (c) Offer help to quit
tobacco use (O); (d) Warn about the dangers of
tobacco (W); (e) Enforce bans on tobacco advertising,
promotion and sponsorship (E); and (f) Raise taxes on
tobacco (R) (see Table 1 for an overview of MPO-
WER measures and how they relate to the WHO
FCTC provisions) [6]. To track the global improve-
ment in the implementation of MPOWER measures,
WHO measures the level of policy achievement for
each measure in each country. In each country, an
MPOWER measure is considered to be mandated at
the highest level when the law requires implementing
all policy components that render such measure most
efficacious in reducing the demand for tobacco prod-
ucts, that is, reducing the prevalence of tobacco use.
For example, the MPOWER measure to protect the
population from tobacco smoke is mandated at the
highest level when the law requires a complete indoor
smoking ban for all workplaces and public places and
not only for some of them. Similarly, the measure to
warn about the dangers of tobacco is mandated at the
highest level when the law requires that health warn-
ings cover an average of at least 50% of the front and
back of the package and has four or more desired fea-
tures. These features include changing the health warn-
ing periodically or including pictures or pictograms.
Tobacco taxes are mandated at the highest level when
excise tobacco taxes amount to at least 75% of the
retail price of a cigarette pack. The closer each country
is to the highest level of policy achievement, the higher
is the MPOWER score the country receives. A detailed
description of the MPOWER scores has been
explained elsewhere [7].
About 5 billion people living in 136 countries, an
equivalent to 65% of the world’s population, are cur-
rently benefiting from at least one of these MPOWER
measures implemented at the highest level. This is a
fivefold increase from the 1.1 billion people benefiting
from tobacco control measures back in 2007.
The world’s population profiting from a basic com-
prehensive policy to assist smoking cessation, or a
comprehensive ban of tobacco advertising, promotion,
and sponsorship has increased about sixfold between
2007 and 2018. The proportion of the world’s popula-
tion benefitting from a comprehensive smoke-free pol-
icy or a legal mandate to have large graphic labels
Table 1. Description of the WHO FCTC articles and their inclusion






General obligations engendered by the
treaty
3–5
Demand-side reduction measures 6–14
Increasing price and tax measures as
effective means to reduce the demand
for tobacco
6 R
Implementing effective measures to
protect from exposure to tobacco
smoke in indoor workplaces, public
transport, indoor public places, and other
public places
8 P
Regulating the contents and emissions
of tobacco products and disclosing
information on their constituents and
emissions
9–10
Banning misleading tobacco packaging
and labeling and ensuring that tobacco
product packages carry large health
warnings and messages describing the
harmful effects of tobacco use
11 W
Promoting public awareness of tobacco
control issues through all available
communication tools
12 W
Banning of all forms of tobacco
advertising, promotion, and sponsorship
13 E
Supporting the reduction in tobacco
dependence and assisting cessation,
including counseling, psychological
support, nicotine replacement, and
education programs
14 O
Eliminating all forms of illicit trade in
tobacco products, prohibiting the sales
of tobacco products to or by minors, and
supporting economically viable
alternative activities to tobacco growing
15–17
Addressing the severe risks posed by
tobacco growing to human health and
the environment
18
Holding the tobacco industry liable for
any abuses and promoting cooperation
among Parties in legal actions relating to
liability
19
Scientifically and technically cooperating
and communicating among Parties,
including tobacco control surveillance
20–22 M
Managing institutional arrangements and
financial resources of the treaty
23–28
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with strong health warnings on tobacco packages has
increased more than eight times in the same period.
While the increase in cigarette taxes is the most
effective tobacco control measure [8], it was also the
least applied in 2018. The total population worldwide
affected by a cigarette tax representing at least 75% of
the retail price has almost doubled since 2007. Another
way to look at the impact of tobacco taxes is to assess
whether tax increases are able to decrease the afford-
ability of tobacco products. By 2018, 44.3% of the
global population lived in countries where cigarettes
became less affordable in the last 10 years. However,
most decreases in cigarette affordability were small.
When considering at least a 10% relative decrease in
cigarette affordability, the world’s population living in
countries achieving this breakthrough is 3.1% [7].
Noticeably, the proportion of the world’s population
exposed to a best-practice mass media campaign
decreased from 2010 until 2018. Few countries run
mass media campaigns regularly, probably due to the
high costs of such campaigns. Only four countries
(Australia, Turkey, the United Kingdom, and Viet
Nam) have run best-practice mass media campaigns
repeatedly since 2010.
2.3. Reducing the prevalence of smoking and
exposure to secondhand smoke
According to the latest WHO estimates that compared
smoking prevalence across countries in 2015, the age-s-
tandardized prevalence of current tobacco smoking
had decreased gradually by 5.9 percentage points since
the beginning of the 21st century, that is, a relative
reduction of 25% or an average decrease of 0.4 per-
centage points per year. WHO estimates that 19.8% of
the world’s population aged ≥ 15 years were current
smokers in 2015 [9]. Denmark, Norway, and Uruguay
were the only countries where current smoking preva-
lence among persons aged ≥ 15 years had been
reduced by ten or more percentage points between
2005 and 2015. During this period, Denmark and
Panama approached most closely the endgame preva-
lence target of 5%, covering more than half of the gap
between current smoking prevalence and target [10].
A recent study [11] estimated that in countries with
higher initial tobacco control preparedness, as mea-
sured by an early MPOWER implementation, the
prevalence of daily smoking decreased by between 0.39
and 0.50 percentage points for each increase in the
MPOWER score, which indicates the strength of the
adopted policies. By contrast, countries with initially
low tobacco control preparedness and high daily
smoking prevalence seem to be struggling to reduce
prevalence despite progress in MPOWER implementa-
tion. Another study indicated that the adoption of at
least one highest level MPOWER policy in 88 coun-
tries between 2007 and 2014 resulted in almost 22 mil-
lion fewer projected smoking-attributable deaths [12].
The health impact of smoke-free policies has been
impressive. The proportion of people protected by
smoke-free legislations worldwide has increased from
3.0% in 2007 to 21.1% in 2018 (Table 2). The largest
countries in the world report significant decreases in
the proportion of people exposed to secondhand
smoke [13–16]. Existing evidence shows that countries
that enact national legislative smoking bans reduce the
population exposure to passive smoke and benefit
from improved health outcomes, specifically of cardio-
vascular diseases [17].
2.4. Tobacco plain packaging has resisted
challenges under trade and investment law
In 2012, Australia became the first country to imple-
ment tobacco plain packaging to counter the tobacco
industry’s use of packaging for both selling cigarettes
and undercutting health warnings. The Australian leg-
islation bans logos, brand imagery, symbols, other
images, colors, and promotional text on tobacco prod-
ucts and tobacco product packaging. It also requires
Table 2. Global progress in the implementation of selected
tobacco control policies at the highest levela. Change between
2007 and 2018 in the population living in countries with selected
policy in billions and as a percentage of the world’s population.
Policy achievement
2007 2018
Billion % Billion %
Total tax on cigarettes ≥ 75% of
retail price
0.5b 7.6b 1.0 13.2
Comprehensive ban of tobacco
advertising, promotion, and
sponsorship
0.2 3.0 1.3 17.1
Comprehensive smoke-free policy 0.2 3.0 1.6 21.1
Well-designed national antitobacco
mass media campaigns
2.4c 36.4c 1.7 22.4
National quitline, and both NRT and
some cessation services cost-
covered
0.4 6.1 2.4 31.6
Strong and large graphic health
warning on the package
0.4 6.1 3.9 51.3
aThe highest level of implementation corresponds to a policy
adopted with all the necessary features to make it as effective as
possible in achieving its intended goals.
bYear corresponds to 2008.
cYear corresponds to 2010.Source: Reference [8] and own elabora-
tion.
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that graphic health warnings cover 75% of the front
and 90% of the back of the tobacco pack [18].
Australia’s plain packaging legislation underwent
three sets of legal challenges. First, big tobacco com-
panies filed a lawsuit in the Australian High Court.
Second, Philip Morris Asia sought to bring down the
Australian legislation under an existing investment
treaty between Australia and Hong Kong. Third,
Cuba, the Dominican Republic, Honduras, Indonesia,
and Ukraine filed a dispute through the World Trade
Organization (WTO). The constitutional challenge
was dismissed in August 2012 [19], and the investment
challenge was rejected in December 2015 [20]. The
WTO decided in June 2020 that Australia’s plain
packaging laws are likely to improve public health
and that they are not unfairly restrictive to trade [21].
The decisions in the case of Australia are not just a
success for public health. They also bring hope for
continuing efforts to defend tobacco control policies
against the attempts of the wealthy tobacco transna-
tionals.
3. Immediate challenges for further
reducing the burden to tobacco-
attributable diseases
The successes described above are significant accom-
plishments. However, key challenges still need to be
addressed to reduce the burden of tobacco-attributable
diseases worldwide in a timely manner.
3.1. Accelerating the decline of smoking
prevalence
The WHO set a relative reduction goal of 30% in
tobacco use and smoking for the period between 2010
and 2025 [22]. Accordingly, the global prevalence of
current smokers should be 15.1% by 2025. However,
based on existing trends, the WHO projects that cur-
rent smokers would be 17.1% of the global population
by 2025 [7]. Therefore, the projected decrease is not
fast enough to reach the 2025 reduction goals set by
the WHO.
The reduction in smoking prevalence has been, so
far, attributed primarily to the increase in the total
population and not necessarily to a reduction in the
number of smokers. It is projected that the total num-
ber of smokers will decrease from 1082 million in 2000
to 1058 million in 2025, a reduction of about 24 mil-
lion or 2.2% [7]. While the number of smokers in the
Americas and Europe will substantially decrease, a net
increase in male smokers in the African, Eastern
Mediterranean, and South-East Asian regions is
expected to hinder a more significant global decrease.
Considering these figures, and that almost one third of
the countries of the world—59 countries in total—have
not yet adopted any MPOWER measures at the high-
est level of achievement, the implementation of cost-ef-
fective tobacco control measures needs to be
expedited.
Strengthening tobacco denormalization through
smoke-free environments and disseminating plain
packaging and large pictorial warnings for all tobacco
products could spearhead progress in many countries.
It seems, however, that a few measures will require
prompt unique determination and diligence. In our
opinion, bolder moves are needed to:
 significantly increase real prices of all tobacco
products through tobacco taxes. Since increasing
taxes is the most effective tobacco control mea-
sure, the tobacco industry devotes many efforts
to derail this measure [23,24]. The main tactics
employed by these companies depend on the tax
structure and administration of each country
and the type of competition they face from other
manufacturers [25].
 disrupt strategies currently applied to engineer
the attractiveness of tobacco products by ban-
ning ingredients that may increase their palata-
bility, including additives and particularly
characterizing flavors.
 ban the most insidious form of tobacco promo-
tion: the tobacco industry’s corporate social
investment or responsibility (CSR) initiatives.
The tobacco industry has always conceived CSR
as a public relations tool to further its business
objectives [26]. It is a form of advertising, pro-
motion, and sponsorship that should be banned.
Whether supporting empowering women [27],
disaster relief and preparedness [28], infectious
disease prevention [29], or efforts against
COVID-19 [30], the tobacco industry’s CSR
activities do little to address the death and suf-
fering caused by tobacco use [31].
To accelerate the implementation of these and other
measures and the decline of smoking, some consider
that a harm reduction strategy should be added to the
existing mix of policies. A harm reduction approach to
tobacco control encourages those smokers that cannot
or are unwilling to stop smoking to switch to using
nicotine in a less harmful form than combustible
tobacco [32]. The public health community is divided
over the value of such a strategy within the parameters
of the existing alternative products, market forces driv-
ing the use of all tobacco and nicotine products, the
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strength of tobacco control policies, and the room of
these to significantly and quickly drive a reduction in
smoking [33]. Resolving this debate is a challenge too.
Meanwhile, there are at least three things that should
be considered to expedite the implementation of the
WHO FCTC, as discussed below.
3.2. Positioning tobacco control in the global
health and development agendas
The global success of the WHO FCTC will be partially
determined by the extent to which governments and
the international community realize that the tobacco
pandemic is a threat to development and the achieve-
ment of the United Nations Sustainable Development
Goals (SDG) [34]. Tobacco use increases healthcare
costs and decreases productivity. Moreover, it feeds
into the vicious circle of poverty. The most disadvan-
taged people spend comparatively less on necessities
such as food, education, and health care to pay for
their addiction to tobacco products [35]. Furthermore,
tobacco farming destroys the environment upon which
the poorest rely to survive. The large amounts of pesti-
cides and fertilizers required to grow tobacco are toxic
and pollute water supplies, in addition to the defor-
estation of their habitat to make room for a nonstaple
crop and to cure tobacco [36]. Despite the inclusion of
a specific target for implementing the WHO FCTC in
the SDGs, for most governments, tobacco control
remains merely a health issue instead of a development
goal [37].
Noncommunicable diseases presently make up 7 of
the world’s top ten causes of death, and tobacco use is
a risk factor for many NCDs [38]. However, tobacco
control is often not prioritized in the health policy
agenda [32]. The global health agenda is presently
dominated by the ‘unfinished agenda’ of communica-
ble disease and maternal and child health in low- and
middle-income countries. Considering the threats of
tobacco use to the public health systems, tobacco con-
trol’s contribution to building stronger economies and
more equitable societies will help to address the ‘unfin-
ished agenda’ and will be crucial for the recovery from
the COVID-19 pandemic in low- and middle-income
countries [39].
The exposure of high-income countries to the
COVID-19 pandemic has highlighted the importance
of controlling communicable diseases also in these
nations. However, this should not distract us from the
fact that COVID-19 has hit the hardest people with
NCDs, for which tobacco use is the main common risk
factor. Smoking increases the risk of hospitalization,
disease severity, and mortality from COVID-19 [40].
Therefore, the COVID-19 pandemic highlights the
importance of investing equal efforts in tackling com-
municable diseases and NCDs, as the latter impact on
the health outcomes of the former, as well as on the
capacity of healthcare systems.
Tobacco control, and NCD prevention, in general,
involves the regulation of industries that produce
goods whose consumption may affect human health.
Some of these industries and their allies are self-serv-
ingly reminding us that the priority for global health is
to prevent communicable disease [41] and responding
quickly and decisively to outbreaks [42] instead of
tobacco control or NCDs [43,44].
3.3. Overcoming the false ‘health versus
economy’ dilemma: the need for a whole-
government approach
The response to the COVID-19 pandemic has made us
painfully aware of the fallacy of presenting the
response to health problems as a trade-off between
lives saved and the economic cost of trying to save
those lives—the health versus the economy dilemma.
Positioning tobacco control within the overall—mainly
economic—priorities of each government is a chal-
lenge, mainly given the intricacies of the broader con-
text of the economic globalization that governments
must navigate.
Parties to the WHO FCTC recognize that a critical
challenge to implementing the treaty in their countries
is the weakness of their multisectoral coordination and
the insufficient support to the implementation of the
WHO FCTC from sectors outside health [45]. A
whole-government approach is needed to succeed in
declining smoking prevalence.
3.4. Countering the Tobacco Industry’s Tactics to
undermine tobacco control measures
The interests of the tobacco industry are irreconcilable
with tobacco control and public health [46]. Conse-
quently, governments should protect the implementa-
tion of their tobacco control policies from the
commercial and other vested interests of the tobacco
industry as mandated by the WHO FCTC. Countering
the tobacco industry’s tactics to undermine tobacco
control measures is not a new challenge [47], but it has
evolved with time. From the same that claimed at
some point that tobacco is not damaging to health
[48], nor addictive [49] or denied targeting youth [50],
we get now that they are committed to a ‘smoke-free
future’ [51]. Their claims are not credible as long as
the industry continues to fight proven policies and
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programs that reduce smoking. Equally, their procla-
mations are not convincing while they misrepresent
regulatory agency decisions about the novel tobacco
products such as heated tobacco products as less
harmful than cigarettes [52]. Ultimately, if anyone in
the tobacco industry is really dedicated to a smoke-
free future, it should immediately stop all marketing of
any kind of cigarettes.
4. Conclusions
Tremendous, although insufficient, progress has been
made on tobacco control during the past twenty years
(Fig. 1). Nevertheless, there are still open challenges,
and several measures remain to be implemented soon:
increasing the real price of all tobacco products
through tobacco taxes, banning the use of additives in
tobacco products, implementing plain packaging for
all tobacco products, and banning tobacco industry’s
corporate social responsibility activities. While imple-
menting these measures, governments and public
health policymakers should be prepared to counteract
undermining tactics of the tobacco industry.
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